There are 2789 resources available
1040O - Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
Presenter: Jeffrey Weber
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1037O - MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)
Presenter: Helen Gogas
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA44 - Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
Presenter: Hirotsugu Kenmotsu
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 1207O and LBA44
Presenter: Natasha Leighl
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Natasha Leighl
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Slides
Webcast
Invited Discussant LBA45 and LBA46
Presenter: Daniel Shao Weng Tan
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Daniel Shao Weng Tan
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Slides
Webcast
Invited Discussant 382O and 386O
Presenter: Pierre Laurent-Puig
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Pierre Laurent-Puig
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Slides
Webcast
Invited Discussant LBA20 and 383O
Presenter: Dominik Modest
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Slides
Webcast